Molecular pathogenesis of chronic myeloid leukemia

SummaryChronic myeloid leukemia (CML) is a  paradigm for effective targeted therapy and is characterized by the hallmarkBCR-ABL1 fusion. Although survival of affected patients has dramatically increased with the introduction of tyrosine kinase inhibitor therapy, kinase-dependent and -independent resistance mechanisms remain a  problem and therefore new clinical strategies based on our growing knowledge of cellular processes are required. New diagnostic opportunities support this task and will change disease management in the future.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research